Physician profile
Nolan E Perez
NPI 1184726986
$150,197.48
in general payments reported to CMS, 2019-2025
29 companies · $41K in 2025
The $41K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,501 · 2020: $189 · 2021: $57.84 · 2022: $1,018 · 2023: $588 · 2024: $103K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $122K · Travel and Lodging: $15K · Food and Beverage: $5,662 · Consulting Fee: $1,518 · Education: $11.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122,294.50 |
| Travel and Lodging | $14,946.14 |
| Food and Beverage | $5,661.68 |
| Consulting Fee | $1,517.50 |
| Education | $11.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $101,304.19 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $35,059.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $6,329.75 | 2021-2025 | |
| Shionogi INC | $4,066.79 | 2019 | |
| Intuitive Surgical, INC. | $628.70 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $625.22 | 2019-2025 | Xifaxan, Trulance |
| Allergan, INC. | $400.00 | 2019 | |
| Axonics, INC. | $290.96 | 2022-2023 | Axonics |
| Boston Scientific Corporation | $246.56 | 2025 | Axonics |
| Romark Laboratories, Lc | $168.40 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $144.94 | 2021-2023 | Lockado |
| Janssen Scientific Affairs, LLC | $142.82 | 2023 | Simponi, Remicade, Tremfya |
| Perspectum Diagnostics Ltd | $111.81 | 2023 | Livermultiscan |
| Baxter Healthcare | $107.56 | 2022 | |
| Lucid Diagnostics INC. | $81.52 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $71.66 | 2023-2025 | Omvoh |
| Teva Pharmaceuticals USA, INC. | $61.80 | 2023 | |
| Genzyme Corporation | $48.52 | 2025 | |
| Ardelyx, INC. | $43.35 | 2024 | Ibsrela |
| Pfizer INC. | $42.30 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.72 | 2019-2020 | |
| Gilead Sciences, INC. | $37.28 | 2021-2024 | Livdelzi |
| Sanofi-Aventis U.S. LLC | $33.35 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $30.66 | 2025 | Iqirvo |
| Enterra Medical, INC. | $21.61 | 2023 | |
| Aimmune Therapeutics, INC. | $21.03 | 2024 | |
| Janssen Biotech, INC. | $20.36 | 2025 | Tremfya |
| Novo Nordisk INC | $16.46 | 2025 | Wegovy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nolan Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.